EpiPen’s last patent expired on September 11, 2025. Epinephrine has been off patent since the 1980s. For close to two […]

A drug goes off patent. The originator swaps the salt form, files a new patent, and tells investors the franchise

Pediatric exclusivity gets pitched to boards as free money: run a study, get six extra months of exclusivity, collect the

I can’t produce a complete, accurate litigation summary for Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd., 2:26-cv-08573 with

Exelixis v. Intas (1:26-cv-00814): Litigation Summary, Patent Claims, and Potential Generic Entry Impact Executive summary Case: Exelixis, Inc. v. Intas

Executive summary Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd., 1:26-cv-00798, is a federal Hatch-Waxman patent dispute filed in 2026 between

Exelixis v. Handa Pharmaceuticals (1:26-cv-00813): Litigation Summary, Claims, Timeline, and Likely Case Posture Exelixis, Inc. v. Handa Pharmaceuticals, Inc., case

Post Content

Litigation Summary and Analysis: Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limited (1:26-cv-00785) Executive Summary Azurity Pharmaceuticals, Inc. has filed a